Core Viewpoint - Rosen Law Firm is investigating potential breaches of fiduciary duties by the directors and officers of Edwards Lifesciences Corporation [1] Group 1: Investigation Details - The investigation is focused on the actions of the directors and officers of Edwards Lifesciences Corporation [1] - Shareholders of Edwards are encouraged to seek more information regarding the investigation [2] Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time [3] - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013 [3] - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering significant amounts for its clients [3]

Upgrades - Seaport Research upgraded Constellation Energy (CEG) to Buy from Neutral with a price target of $407, anticipating more datacenter power deal announcements and positive earnings revisions for thermal IPPs before year-end [2] - Wolfe Research upgraded Otis Worldwide (OTIS) to Outperform from Peer Perform with a price target of $109, noting that downside risk to Q4 outlook is widely anticipated but offsetting positive developments could drive more bullish positioning [3] - JPMorgan upgraded Ionis Pharmaceuticals (IONS) to Overweight from Neutral with a price target of $80, up from $49, citing multiple launches that position the company on a path to breakeven [4] - Needham upgraded Penumbra (PEN) to Buy from Hold with a price target of $326, expecting significant growth acceleration in 2026 due to upcoming product launches and easing headwinds in China [4] - Deutsche Bank upgraded Northrop Grumman (NOC) to Buy from Hold with a price target of $700, up from $575, forecasting strong free cash flow post-2028 as key programs become cash profitable [5] Downgrades - HSBC downgraded Intel (INTC) to Reduce from Hold with a price target of $24, up from $21.25, indicating that while short-term deal announcements may drive stock higher, sustainable turnaround relies on fab execution [6] - JPMorgan downgraded FedEx (FDX) to Neutral from Overweight with a price target of $274, down from $284, based on recent channel checks suggesting a lower multiple for FedEx's freight segment [6] - Oppenheimer downgraded Edwards Lifesciences (EW) to Perform from Outperform with no price target, indicating a structural nature to the downgrade despite potential TAVR upside in Q3 [6] - BofA downgraded Freshpet (FRPT) to Neutral from Buy with a price target of $60, down from $81, citing deteriorating growth in the pet food category due to slowed pet adoptions and reduced consumer spending [6] - Oppenheimer downgraded Incyte (INCY) to Perform from Outperform with a price target of $82, up from $81, due to high expectations for several products and new management [6]

Core Insights - Edwards Lifesciences Corporation (EW) is valued at a market cap of $45.2 billion and specializes in products for advanced cardiovascular diseases, particularly known for its SAPIEN transcatheter aortic valve replacement products [1] - The company is set to announce its fiscal Q3 earnings for 2025 on October 30, 2023, with analysts expecting a profit of $0.59 per share, a decrease of 11.9% from the previous year [2] Financial Performance - For fiscal 2025, analysts project EW to report a profit of $2.50 per share, reflecting a 2.9% increase from $2.43 per share in fiscal 2024, with further growth expected to $2.78 per share in fiscal 2026, an 11.2% year-over-year increase [3] - In Q2, EW reported an 11.9% year-over-year revenue increase to $1.5 billion, surpassing consensus estimates by 2.7%, and an adjusted EPS of $0.67, which was 8.1% higher than the previous year [5] Stock Performance - EW's shares have increased by 17.9% over the past 52 weeks, outperforming the S&P 500 Index's 17.8% rise and the Health Care Select Sector SPDR Fund's 4.4% decline during the same period [4] - Following the release of better-than-expected Q2 results, EW's shares surged by 5.5% in the subsequent trading session [5] Analyst Ratings - Wall Street analysts maintain a "Moderate Buy" rating for EW, with 15 out of 31 analysts recommending "Strong Buy," one suggesting "Moderate Buy," 14 advising "Hold," and one indicating "Strong Sell" [6] - The mean price target for EW is set at $86.83, suggesting a potential upside of 12.7% from current levels [6]

Group 1 - East West Petroleum Corp. has completed the capital reduction and special distribution as previously announced [1] - The company will proceed with the name change from "East West Petroleum Corp." to "East West Minerals Ltd." and a share consolidation on a ten-for-one basis, expected to be implemented around October 6, 2025 [2]

Core Viewpoint - Rosen Law Firm is investigating potential breaches of fiduciary duties by the directors and officers of Edwards Lifesciences Corporation [1] Group 1: Investigation Details - The investigation pertains to potential breaches of fiduciary duties by the leadership of Edwards Lifesciences Corporation [1] - Investors who own shares of Edwards stock are encouraged to seek more information through the Rosen Law Firm's website or contact them directly [2] Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time [3] - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013 [3] - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering significant amounts for its clients [3]

Core Viewpoint - Rosen Law Firm is investigating potential breaches of fiduciary duties by the directors and officers of Edwards Lifesciences Corporation (NYSE: EW) [1]. Group 1: Company Overview - Edwards Lifesciences Corporation is under scrutiny for possible fiduciary duty violations by its leadership [1]. Group 2: Legal Context - Rosen Law Firm specializes in securities class actions and shareholder derivative litigation, emphasizing the importance of selecting qualified legal counsel with a successful track record [3]. - The firm has achieved significant settlements in the past, including the largest securities class action settlement against a Chinese company at the time and over $438 million secured for investors in 2019 alone [3].

Core Viewpoint - Rosen Law Firm is investigating potential breaches of fiduciary duties by the directors and officers of Edwards Lifesciences Corporation [1] Group 1 - The investigation is focused on the actions of the company's directors and officers [1] - Shareholders of Edwards Lifesciences Corporation are encouraged to seek more information regarding the investigation [1]

Group 1 - East West Petroleum Corp. is in the process of completing a capital reduction and special distribution, with further updates to be provided once completed [1] - The company has announced a proposed name change to "East West Minerals Ltd." and a share consolidation on a ten-for-one basis, which will be implemented after the special distribution is completed [2] Group 2 - The TSX Venture Exchange has approved the name change and share consolidation, but these actions are contingent upon the completion of the special distribution [2]

Core Thesis - Edwards Lifesciences Corporation is experiencing a bullish trend due to strong Q2 results, marking a return to double-digit growth after several quarters of slower momentum [2][5] - The company's stock price was $76.05 as of September 15th, with trailing and forward P/E ratios of 31.82 and 28.17 respectively [1] Financial Performance - Q2 revenue increased by 11% year-over-year, exceeding consensus expectations of 8%, while adjusted EPS was $0.67, beating estimates by 8% [2] - The stock reacted positively, climbing 5% on the day and showing a 16% rebound from January 2025 lows [2] Market Position - Edwards Lifesciences is recognized as the highest-quality company in the structural heart disease space, with its Sapien platform being the only TAVR approved for asymptomatic patients in both the U.S. and Europe [2] - Improved durability data for Sapien strengthens its competitive position against surgical valve replacements [3] Segment Performance - TAVR revenue grew by 8%, while transcatheter mitral and tricuspid therapies (TMTT) surged by 57% due to strong adoption of Evoque and Pascal [3] - Surgical revenue also grew by 7%, aligning with long-term targets [3] Future Outlook - Management raised 2025 revenue guidance to 9–10% and EPS guidance to the high end of the $2.40–2.50 range [4] - Fair value estimates imply a five-year CAGR of 12.6% based on a valuation model assuming 10% revenue growth and expanding margins [4] - Despite recent gains, Edwards remains undervalued, presenting attractive upside potential relative to the broader market [4]

Core Viewpoint - East West Petroleum Corp. is executing a capital reduction of approximately $2,714,570 and a special distribution of $0.03 per common share to its shareholders [1][2][3] Group 1: Capital Reduction and Special Distribution - The capital reduction will involve re-designating existing common shares as Class A Common Shares and creating a new class of common shares [3] - Each Class A Common Share will be exchanged for one New Common Share and a pro rata share of the distribution, amounting to $0.03 in cash per Class A Common Share [3] - The total reduction in stated capital will be approximately $2,714,570, and Class A Common Shares will be eliminated as a class [3] Group 2: Payment Process - The special distribution will be paid by Computershare Investor Services Inc., with registered shareholders on record by September 15, 2025, receiving their payment around September 19, 2025 [2] - Beneficial shareholders will receive payment through their intermediaries, each following their own payment process [2] Group 3: Trading Procedures - The TSX Venture Exchange has determined that "Due Bill" trading procedures will apply, allowing purchasers of shares during the specified period to receive the distribution instead of the seller [4] - Due Bills will be redeemed on September 22, 2025, after all trades with attached Due Bills have settled [4]